NCT06883526 Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
| NCT ID | NCT06883526 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| Condition | Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-05-16 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2025-05-16 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
Eligibility Criteria
Inclusion Criteria: * Fully understand this study and voluntarily sign the ICF； * Age ≥18 at ICF signing, regardless of gender； * Histologically confirmed relapsed or refractory lymphoma. Exclusion Criteria: * Lymphoma with known CNS involvement； * Severe cardiovascular/cerebrovascular diseases. * Any other reason deeming the participant unsuitable for the study, as judged by the investigator.
Contact & Investigator
Jason Wu
STUDY CHAIR
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Frequently Asked Questions
Who can join the NCT06883526 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06883526 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06883526 currently recruiting?
Yes, NCT06883526 is actively recruiting participants. Contact the research team at jiasy@zelgen.com for enrollment information.
Where is the NCT06883526 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06883526 clinical trial?
NCT06883526 is sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. The principal investigator is Jason Wu at Suzhou Zelgen Biopharmaceuticals Co.,Ltd. The trial plans to enroll 60 participants.